Adherence to diabetes medication in individuals with schizophrenia: A systematic review of rates and determinants of adherence

Clinical Schizophrenia and Related Psychoses

Volumn 10, Issue 4, 2017, Pages 191-200

  Gorczynski, Paul ^a   Patel, Hiren ^b   Ganguli, Rohan ^c  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diabetes; Medication adherence; Schizophrenia

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; NEUROLEPTIC AGENT; ORAL ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE MONITORING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; ATTITUDE TO HEALTH; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG DEPENDENCE; HOMELESS PERSON; METABOLISM; MOTIVATION; PSYCHOLOGY; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA;

ATTITUDE TO HEALTH; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HOMELESS PERSONS; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; MOTIVATION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 85015352911     PISSN: 19351232     EISSN: 19412010     Source Type: Journal    
DOI: 10.3371/CSRP.GOPA.013114     Document Type: Review

References (60)

1. Holt R I G, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab 2009;11(7):665-679.
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
3. Chuang HT, Mansell C, Patten SB. Lifestyle characteristics of psychiatric outpatients. Can J Psychiatry 2008;53(4):260-266.
4. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012;25(2):83-88.
5. Newcomer J W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(1 Suppl):1-93.
6. Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry 2008;42(5):369-381.
7. Schoepf D, Potluri R, Uppal H, Natalwala A, Narendran P, Heun R. Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. Eur Psychiatry 2012;27(1):32-42.
8. De Hert M, Schreurs V, Vancampfort D, Van Winkell R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009;8(1):15-22.
9. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Tromb Vasc Biol 2006;26(5):968-976.
10. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150(6):1115-1121.
11. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30(1):67-76.
12. Strassnig M, Brar JB, Ganguli R. Health-related quality of life, adiposity, and sedentary behavior in patients with early schizophrenia: preliminary study. Diabetes Metab Syndr Obes 2012;5:389-394.
13. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80(1):45-53.
14. Suvisaari J, Perälä J, Saarni SI, Härkänen T, Pirkola S, Joukamaa M, et al. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur Arch Psychiatry Clin Neurosci 2008;258(3):129-136.
15. Woo V, Harris SB, Houlden RL. Canadian Diabetes Association Position Paper: Antipsychotic medications and associated risks of weight gain and diabetes. Can J Diabetes 2005;29:111-112.
16. Ludwig S, Clement M, Dunbar P, Johnson JA. Organization of diabetes care. Can J Diabetes 2008;32 (1 Suppl):S20-S24.
17. Vermeire E, Wens J, Van Royen P, Biot Y, Hernshaw H, Lindenmeyer A. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database of Syst Rev 2005;2: CD003638.
18. Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006;12(6):466-471.
19. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(Suppl):S11-S63.
20. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32 (1 Suppl):S1-S201.
21. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2005;27(5):1218-1224.
22. Cimo A, Stergiopoulos E, Cheng C, Bonato S, Dewal CS. Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review. BMC Psychiatry 2012;12:24.
23. Goldberg RW, Kreyenbuhl JA, Medoff DR, Dickerson FB, Wohlheiter K, Fang J, et al. Quality of diabetes care among adults with serious mental illness. Psychiatr Serv 2007;58(4):536-543.
24. Dickerson FB, Goldberg RW, Brown CH, Kreyenbuhl JA, Wohlheiter K, Fang L, et al. Diabetes knowledge among persons with serious mental illness and type 2 diabetes. Psychosomatics 2005;46(5):418-424.
25. Peeters B, Van Tongelen I, Boussery K, Mehuys E, Remon J P, Willems S. Factors associated with medication adherence to oral hypoglycaemic agents in different ethnic groups suffering from Type 2 diabetes: a systematic literature review and suggestions for further research. Diabet Med 2011;28(3):262-275.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA; 1994.
27. Delamater AM. Improving patient adherence. Clinical Diabetes 2006;24(2):71-77.
28. Meichenbaum D, Turk DC. Facilitating treatment adherence: a practitioner's guidebook. New York (NY): Plenum Press; 1987.
29. Haynes RB, Taylor DW, Sackett DL. Compliance in healthcare. Baltimore (MD): Johns Hopkins University Press; 1979.
30. Juvonen H, Reunanen A, Haukka J, Muhonen M, Suvisaari J, Arajärvi R, et al. Incidence of schizophrenia in a nationwide cohort of patients with type 1 diabetes mellitus. Arch Gen Psychiatry 2007;64(8):894-899.
31. Trost SG, Owen N, Bauman AE, Sallis JF, Brown W. Correlates of adults' participation in physical activity: review and update. Med Sci Sports Exerc 2002;34:1996-2001.
32. Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S, De Hert M. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand 2012;125(5):352-362.
33. Faulkner G, Gorczynski P. Evidence of impact of physical activity on schizophrenia. In: Clow A, Edmunds S, editors. Physical activity and mental health. Champaign (IL): Human Kinetics; 2013. p. 215-235.
34. Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M. Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophr Bull 2010;36(2):428-435.
35. Kreyenbuhl J, Leith J, Medoff DR, Fang L, Dickerson FB, Brown CH, et al. A comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness. Psychiatry Res 2011;188(1):109-114.
36. Dolder CR, Lacro J P, Jeste DV. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psycho-som Med 2003;65:156-162.
37. Piette JD, Heisler M, Ganoczy D, McCarthy JF, Valenstein M. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatr Serv 2007;58(2):207-212.
38. Farley JF, Hansen RA, Yu-Isenberg KS, Maciejewski ML. Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions. Prim Care Companion CNS Disord 2012;14(3): PCC.11m01324.
39. Hansen RA, Maciejewski M, Yu-Isenberg K, Farley JF. Adherence to antipsychot-ics and cardiometabolic medication: association with health care utilization and costs. Psychiatr Serv 2012;63(9):920-928.
40. Gilmer T P, Dolder CR, Lacro J P, Folsom D P, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161(4):692-699.
41. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988;26(8):814-823.
42. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, et al. Pharmacy data identify poor adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40(8):630-639.
43. Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004;30(2):255-264.
44. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm 1992;49(7):1691-1696.
45. Steiner JF, Prochazka AV. Te assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50(1):105-116.
46. Svarstad BL, Chewnig BA, Sleath BL, Claesson C. Te brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 1999;37(2):113-124.
47. Horne R, Weinman J, Hankins M. Te Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.
48. Patterson TL, Lacro J, McKibbin CL, Moscona S, Hughs T, Jeste D V. Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia. J Clin Psychopharmacol 2002;22(1):11-19.
49. Randolph C. RBANS Manual: Repeatable Battery for the Assessment of Neuro-psychological Status. San Antonio (TX): Psychological Corporation; 1998.
50. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25(9):2303-2310.
51. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. Te significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62(1):76-87.
52. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118(5A):27s-34s.
53. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43(6):521-530.
54. Wild H. Te economic rationale for adherence in the treatment of type 2 diabetes mellitus. Am J Manag Care 2012;18 (3 Suppl):S43-S48.
55. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159(10):1653-1664.
56. Medical Research Council (MRC). Developing and evaluating complex interventions: new guidance. London (UK): MRC; 2008.
57. Kirkman S, Rowan-Martin M, Herrera V, Hawk G, Fonseca V, Schmidttdi-el JA, et al. Determinants of non-adherence to diabetes medication. ADA 2013; Abstract:209-OR.
58. Hawkins R P, Kreuter M, Resnicow K, Fishbein M, Dijkstra A. Understanding tailoring in communicating about health. Health Educ Res 2008;23(3):454-466.
59. Kreuter M W, Wray RJ. Tailored and targeted health communication: strategies for enhancing information relevance. Am J Health Behav 2002;27 (3 Suppl):S227-S232.
60. Zacker RJ. Exercise: a component of diabetes management. Diabetes Spectrum 2004;17(3):142-144.